News

AI-Driven Innovations to Propel Indian Pharma Industry to $130 Billion by 2030

The industry, currently valued at $58 billion, is projected to nearly double to $130 billion by 2030. This growth is supported by favorable policies, a skilled workforce, and India’s burgeoning digital talent, according to Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance (IPA).

• By Newsdesk
• New Delhi
• Dec 26, 2024

News

The Indian pharmaceutical sector is poised for transformative growth, leveraging technological advancements such as artificial intelligence (AI), machine learning, and precision medicine. These innovations are expected to redefine drug discovery, manufacturing, and patient care, positioning India as a global hub for affordable, high-quality pharmaceuticals.

The industry, currently valued at $58 billion, is projected to nearly double to $130 billion by 2030. This growth is supported by favorable policies, a skilled workforce, and India’s burgeoning digital talent, according to Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance (IPA). "Quality, innovation, and global reach will be key drivers as the sector continues to evolve," Jain noted.

A New Era of Innovation and Excellence

Indian pharmaceutical companies are increasingly focusing on research and development to expand their specialty drug portfolios and tap into high-value segments like CAR-T cell therapy, mRNA vaccines, and complex molecule development. These efforts align with the government’s forthcoming Promotion of Research & Innovation Programme, designed to accelerate innovation across the industry.

Patent expirations for blockbuster biologics by 2025 also present significant opportunities in the global biosimilars market. This momentum is further bolstered by production-linked incentive (PLI) schemes, which have already catalyzed greenfield projects for critical drug ingredients like Penicillin G and Clavulanic acid.

Strengthened Regulatory Frameworks

Enhanced regulatory policies are set to streamline the adoption of cutting-edge therapies while ensuring patient safety. "Collaboration among policymakers, academia, and industry stakeholders will address unmet medical needs, particularly in underserved regions," said Anil Matai, Director General of the Organisation of Pharmaceutical Producers of India (OPPI). Adherence to ethical marketing practices under the Uniform Code of Pharmaceutical Marketing Practices (UCPMP) is expected to strengthen trust and transparency within the healthcare ecosystem.

Healthcare and Medtech Growth Trajectories

India's healthcare sector is also on a robust growth path, with the hospital market projected to expand from $99 billion in 2023 to $194 billion by 2032. "The integration of AI, robotics, and telemedicine will enhance diagnostics and operational efficiency, leading to improved patient outcomes," stated Fortis Healthcare MD & CEO Ashutosh Raghuvanshi.

Meanwhile, the medical technology (medtech) sector is set to reach $50 billion by FY2030. Himanshu Baid, MD of Poly Medicure, emphasized the importance of R&D investments, saying, "The future belongs to companies that can develop transformative technologies addressing dynamic healthcare needs."

Diagnostics Industry Transformation

The diagnostics segment is experiencing rapid growth, driven by rising preventive healthcare awareness, an ageing population, and broader insurance coverage. "Genomics, digitalization, and AI-driven analytics will shape the future of diagnostics," said Ameera Shah, Promoter and Executive Chairperson of Metropolis Healthcare. She also highlighted the importance of industry consolidation to overcome fragmentation and ensure uniform quality.

A Global Role in Advancing Healthcare

As India cements its role in global healthcare, its pharmaceutical and healthcare industries are on a trajectory of innovation, collaboration, and sustained growth. These advancements promise to enhance access, affordability, and quality, solidifying India’s position as a leader in the global healthcare ecosystem.